Format

Send to

Choose Destination
J Pharm Biomed Anal. 2019 Mar 20;166:197-204. doi: 10.1016/j.jpba.2019.01.017. Epub 2019 Jan 11.

Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.

Author information

1
Karmanos Cancer Institute, Wayne State University, Detroit, MI, 48201, United States.
2
Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ, 85013, United States.
3
Karmanos Cancer Institute, Wayne State University, Detroit, MI, 48201, United States. Electronic address: lijin@karmanos.org.

Abstract

Ribociclib is a selective, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) 4/6, which has therapeutic potential for a variety of cancer types. This study was to develop and validate a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for determining total and unbound concentrations of ribociclib in human plasma and brain tumor tissue samples. Plasma and tumor homogenate samples were extracted using protein precipitation with acetonitrile. Unbound fraction in plasma or tumor homogenate was determined by equilibrium dialysis method. Chromatographic separation was achieved based on aqueous normal-phase chromatography mechanism on a Waters XBridge Amide column under isocratic elution with acetonitrile-ammonium formate (10 mM, pH 3) (75:25, v/v) at a flow rate of 0.8 mL/min. Ribociclib and the internal standard ([13C6]ribociclib) were monitored at the mass transitions m/z, 435.3 > 367.2 and 441.3 > 373.2, respectively, using positive electrospray ionization mode. The lower limit of quantitation (LLOQ) was 0.5 nM of ribociclib in plasma. Linear calibration curve was established at the concentration range of 0.5-1000 nM in plasma. Intra- and inter-day precision and accuracy were within the generally accepted criteria for bioanalytical method. The developed method was successfully applied to determine the plasma pharmacokinetics and central nervous system penetration of ribociclib in patients with malignant primary brain cancer.

KEYWORDS:

Aqueous normal-phase liquid chromatography; Blood-brain barrier; Liquid chromatography with tandem mass spectrometry (LC–MS/MS); Pharmacokinetics; Protein binding; Ribociclib

PMID:
30660034
DOI:
10.1016/j.jpba.2019.01.017

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center